| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.65(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.26 - $43.27 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
| Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
| Total People Bought |
0 |
0 |
6 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
7 |
| Total Shares Sold |
154,667 |
359,132 |
611,027 |
1,200,893 |
| Total Sell Value |
$6,418,967 |
$14,072,755 |
$21,003,717 |
$39,590,443 |
| Total People Sold |
2 |
8 |
8 |
10 |
| Total Sell Transactions |
5 |
21 |
27 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Akamine Scott |
Chief Legal Officer |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,796 |
14,309 |
|
- |
|
| Dipietro Kenneth |
Chief Human Resources Officer |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,913 |
30,919 |
|
- |
|
| Renaud Ronald C Jr |
President & CEO |
• • – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
160,452 |
160,452 |
|
- |
|
| Tregoning Kathleen |
See Remarks |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,804 |
13,804 |
|
- |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,825 |
24,825 |
|
- |
|
| Bodenrader Mark |
See Remarks |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,284 |
25,613 |
|
- |
|
| Altschuller Susan |
Chief Financial Officer |
• – – |
2023-12-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,721 |
30,721 |
|
- |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2023-12-15 |
4 |
S |
$41.39 |
$310,393 |
D/D |
(7,500) |
0 |
|
-4% |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2023-12-15 |
4 |
OE |
$9.88 |
$74,100 |
D/D |
7,500 |
7,500 |
|
- |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2023-12-07 |
4 |
AS |
$41.37 |
$413,700 |
D/D |
(10,000) |
0 |
|
3% |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2023-12-07 |
4 |
OE |
$3.50 |
$35,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2023-12-07 |
4 |
AS |
$41.37 |
$413,700 |
D/D |
(10,000) |
513 |
|
3% |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2023-12-07 |
4 |
OE |
$13.17 |
$131,700 |
D/D |
10,000 |
10,513 |
|
- |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2023-12-05 |
4 |
AS |
$35.00 |
$262,500 |
D/D |
(7,500) |
513 |
|
16% |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2023-12-05 |
4 |
OE |
$13.17 |
$98,775 |
D/D |
7,500 |
8,013 |
|
- |
|
| Coles N Anthony |
|
– • – |
2023-11-14 |
4 |
AS |
$25.13 |
$573,455 |
D/D |
(22,824) |
2,704 |
|
66% |
|
| Coles N Anthony |
|
– • – |
2023-11-14 |
4 |
OE |
$3.50 |
$79,884 |
D/D |
22,824 |
25,528 |
|
- |
|
| Coles N Anthony |
|
– • – |
2023-11-08 |
4 |
AS |
$25.16 |
$2,516 |
D/D |
(100) |
2,704 |
|
73% |
|
| Coles N Anthony |
|
– • – |
2023-11-08 |
4 |
OE |
$3.50 |
$350 |
D/D |
100 |
2,804 |
|
- |
|
| Coles N Anthony |
|
– • – |
2023-11-07 |
4 |
AS |
$25.02 |
$677,555 |
D/D |
(27,076) |
2,704 |
|
69% |
|
| Coles N Anthony |
|
– • – |
2023-11-07 |
4 |
OE |
$3.50 |
$94,766 |
D/D |
27,076 |
29,780 |
|
- |
|
| Coles N Anthony |
|
– • – |
2023-11-03 |
4 |
AS |
$25.43 |
$1,561,458 |
D/D |
(61,401) |
2,704 |
|
61% |
|
| Coles N Anthony |
|
– • – |
2023-11-03 |
4 |
OE |
$3.50 |
$214,904 |
D/D |
61,401 |
64,105 |
|
- |
|
| Coles N Anthony |
|
– • – |
2023-11-02 |
4 |
AS |
$25.19 |
$972,239 |
D/D |
(38,599) |
2,704 |
|
70% |
|
| Coles N Anthony |
|
– • – |
2023-11-02 |
4 |
OE |
$3.50 |
$135,097 |
D/D |
38,599 |
41,303 |
|
- |
|
181 Records found
|
|
Page 2 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (0.09%) 
